Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
A new trial revealed that a weight loss Drugs taken monthly helps people lose 20% of their body weight.
Other weight loss drugs such as OzempicWegovy and Mounjaro have become popular in the United States now, researchers are testing a new GLP-1 medication known as Maritide which could be competitive on the market.
Marititide, the manufacturer of Californian drugs Amgen, is different from other weight loss drugs because it also has a monoclonal antibody, which allows the medication to stay in the body longer, according to NBC News.
In a new test published in The New England Journal of Medicine, The doctors of the Yale School of Medicine and other institutions analyzed the health of nearly 600 participants. They were divided into two groups: those with obesity and people with type 2 diabetes and obesity.
The test revealed that those who have obesity alone who were treated with maritid lost up to around 20% of their body weight, on average, after 52 weeks. Those who have obesity alone who did not take the maritide lost up to 2.6% of their body weight on average.
Participants who suffered from diabetes and obesity lost on average up to 17% of their body weight, while taking maritid, according to study authors. Those who suffer from the two diseases that were not on maritid lost up to 1.4% of their body weight, on average.
“Maritide has provided high efficiency, including sustained weight loss without a set in the study of phase 2 of 52 weeks and significant improvements in cardiometabolic risk factors, representing a decisive advance for the field of obesity,” said Dr. Jay Bradner, executive vice-president of research and development in AMGEN, in a statement announcing the results.
Marititid researchers said gastrointestinal problems were “common” with the drug, but the side effects of the drug are similar to that of other GLP-1 drugs. They include nausea, abdominal pain and vomiting.
“Gastrointestinal undesirable events were common with Maridebart’s Cafraglutide, although less frequent with a dose climb and a lower starting dose. No unexpected security signal emerged,” they wrote.
In particular, drug must be given to a low starting dose To limit these side effects and there have been high stop rates in the mid-term trial. The company plans to adjust its dosage, New Stat note.
The company said it was planning to start additional studies this year in patients with several serious health problems.
Ozempic and similar drugs can help patients lose 15 to 20% of their body weight, according to Department of Surgery of Columbia University. Ozempic drugs and other GLP-1s are taken every week, but the maritide has only to be taken monthly, which makes it more practical for patients.
“It is always easier for patients to have to take something once a month,” said Dr. Michelle Ponder, assistant medicine professor at the Duke University School of Medicine in North Carolinasaid to NBC.
Ponder, which was not part of the maritid test, added: “Many patients we see in endocrinology are diabetic patients, and therefore they would take several insulin blows a day.
